Brian Williams, MD
Pulmonary Disease · Lubbock, TXNPI 1912028622
Payments from drug & device makers
Across 321 payments — averaging $60.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$14K
- GSK$1K
- Grifols USA, LLC$721
- Boehringer Ingelheim$645
- AstraZeneca$548
- Actelion Pharmaceuticals US, Inc.$251
- plus $2K from 33 others
What the payments were for
- Travel & lodging$6874%
- Food & beverage$5,80430%
- Education$13,00067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $13,865 |
| GSK | 71 | $1,136 |
| Grifols USA, LLC | 37 | $721 |
| Boehringer Ingelheim | 31 | $645 |
| AstraZeneca | 34 | $548 |
| Actelion Pharmaceuticals US, Inc. | 16 | $251 |
| Sanofi | 9 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $176 |
| Pfizer | 9 | $175 |
| Regeneron Healthcare Solutions, Inc. | 9 | $166 |
| Mylan Specialty L.p. | 10 | $158 |
| Amgen | 7 | $148 |
| Johnson & Johnson | 7 | $130 |
| Baxter Healthcare | 6 | $119 |
| AbbVie(2 entities) | 8 | $114 |
| Insmed, Inc. | 5 | $111 |
| Tolmar, Inc. | 4 | $76 |
| Abiomed | 3 | $75 |
| Medivance, Inc. | 1 | $75 |
| Merck | 5 | $66 |
| Inspire Medical Systems, Inc. | 3 | $57 |
| Mallinckrodt Hospital Products Inc. | 3 | $56 |
| Electromed, Inc. | 4 | $53 |
| Harmony Biosciences LLC | 2 | $52 |
| Sanofi US Services Inc. | 1 | $41 |
| Inari Medical, Inc. | 1 | $40 |
| Philips North America LLC | 2 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Ambu Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Boston Scientific | 1 | $18 |
| Gilead | 1 | $18 |
| Bayer | 1 | $17 |
| United Therapeutics Corporation | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Pharmaand GmbH | 1 | $17 |
| Convatec Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$9,000
- DAVINCI XI$4,000
- Da Vinci Surgical System$710
How this compares
$19,491 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $420,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 144 | $106,447 |
| Dupixent PenDupilumab | 27 | $105,824 |
| Ambrisentan | 14 | $39,657 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $30,067 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $23,775 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $23,277 |
| EliquisApixaban | 25 | $14,151 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 17 | $6,920 |
| Tiotropium Bromide | 14 | $5,557 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,280 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,830 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,071 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,534 |
| Varenicline Tartrate | 15 | $2,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $645 | $444,52270 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $1,136 | $133,795203 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $548 | $41,81771 claims |
| PfizerEliquis | $175 | $14,15125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Lubbock
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.